Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

Shares of biotech Summit Therapeutics ( SMMT 9.31%) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...

Merck (MRK) stock in focus as the company eyes 2025 launch of subcutaneous Keytruda amid a looming patent cliff for its ...